Table 3.
Summary of findings for MAGE reduction compared DPP-IV inhibitors to other OADs based on the GRADE approach.
| Outcome | No. of Participants (studies) | Limitation | Inconsistency | Indirectness | Imprecision | Publication bias | Mean difference* (95% CI) | Quality of Evidence |
|---|---|---|---|---|---|---|---|---|
| Overall | 304 (8) | No serious | No serious | No serious | No serious | Undetected | −14.61 (−19.00, −10.21) | ⊕⊕⊕⊕ High |
| Compared to sulfonylurea | 279 (7) | No serious | No serious | No serious | No serious | Undetected | −14.93 (−21.60,−8.26) | ⊕⊕⊕⊕ High |
| According to types of therapy | ||||||||
| Stepwise addition therapy | 124 (4) | No serious | No serious | No serious | No serious | Undetected | −9.26 (−16.40, −2.11) | ⊕⊕⊕⊕ High |
| Initial combination therapy | 128 (3) | No serious | Serious | No serious | No serious | Undetected | −23.36 (−30.45, −16.26) | ⊕⊕⊕◯ Moderate |
| According to HbA1c | ||||||||
| HbA1c ≥7.5% | 205 (5) | No serious | No serious | No serious | No serious | Undetected | −12.78 (−18.70, −6.85) | ⊕⊕⊕⊕ High |
| HbA1c ≤7.5% | 99 (3) | No serious | No serious | No serious | No serious | Undetected | −16.84 (−23.39, −10.29) | ⊕⊕⊕⊕ High |
CI, Confidence Interval; ICU, intensive care unit; MICU, medical intensive care unit; PICU, pediatric intensive care unit; observational, observational study; RCT, randomized controlled trial. ⊕ = attainment of Grading of Recommendations, Assessment, Development, and Evaluation criteria. *p < 0.05.